• 1
    Tatemoto K, Rökaeus Å, Jörnvall H, et al. Galanin: a novel biologically active peptide from porcine intestine. FEBS Lett 1983;164: 1248.
  • 2
    Melander T, Hökfelt T, Rökaeus Å. Distribution of galaninlike immunoreactivity in the rat central nervous system. J Comp Neurol 1986;248: 475517.
  • 3
    Perez SE, Wynick D, Steiner RA, et al. Distribution of galaninergic immunoreactivity in the brain of the mouse. J Comp Neurol 2001;434: 15885.
  • 4
    Iismaa TP, Shine J. Galanin and galanin receptors. Results Probl Cell Differ 1999;26: 25791.
  • 5
    Branchek TA, Smith KE, Gerald C, et al. Galanin receptor subtypes. Trends Pharmacol Sci 2000;21: 10917.
  • 6
    Merchenthaler I, Lopez FJ, Negro-Vilar A. Anatomy and physiology of central galanin-containing pathways. Prog Neurobiol 1993;40: 71169.
  • 7
    Hökfelt T, Bartfai T, Crawley J. (eds.) Galanin: basic research discoveries and therapeutic implications. Ann NY Acad Sci 1998;863: 1469.
  • 8
    Fisone G, Wu CF, Consolo S, et al. Galanin inhibits acetylcholine release in the ventral hippocampus of the rat: histochemical, autoradiographic, in vivo, and in vitro studies. Proc Natl Acad Sci USA 1987;84: 733943.
  • 9
    Dutar P, Lamour Y, Nicoll RA. Galanin blocks the slow cholinergic EPSP in CA1 pyramidal neurons from ventral hippocampus. Eur J Pharmacol 1989;164: 35560.
  • 10
    Zini S, Roisin MP, Langel U, et al. Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus. Eur J Pharmacol 1993;245: 17.
  • 11
    Sakurai E, Maeda T, Kaneko S, et al. Galanin inhibits long-term potentiation at Schaffer collateral-CA1 synapses in guinea-pig hippocampal slices. Neurosci Lett 1996;212: 214.
  • 12
    Fuxe K, Jansson A, Diaz-Cabiale Z, et al. Galanin modulates 5-hydroxytryptamine functions: focus on galanin and galanin fragment/5-hydroxytryptamine1A receptor interactions in the brain. Ann N Y Acad Sci 1998;863: 27490.
  • 13
    Kehr J, Yoshitake T, Wang FH, et al. Galanin is a potent in vivo modulator of mesencephalic serotonergic neurotransmission. Neuropsychopharmacology 2002;27: 34156.
  • 14
    Mazarati AM, Halaszi E, Telegdy G. Anticonvulsive effects of galanin administered into the central nervous system upon the picrotoxin-kindled seizure syndrome in rats. Brain Res 1992;589: 1646.
  • 15
    Mazarati AM, Liu H, Soomets U, et al. Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. J Neurosci 1998;18: 100707.
  • 16
    Mazarati AM, Hohmann JG, Bacon A, et al. Modulation of hippocampal excitability and seizures by galanin. J Neurosci 2000;20: 627681.
  • 17
    Kokaia M, Holmberg K, Nanobashvili A, et al. Suppressed kindling epileptogenesis in mice with ectopic overexpression of galanin. Proc Natl Acad Sci U S A 2001;98: 1400611.
  • 18
    Jacoby AS, Hort YJ, Constantinescu G, et al. Critical role for GALR1 galanin receptor in galanin regulation of neuroendocrine function and seizure activity. Mol Brain Res 2002;107: 195200.
  • 19
    Gall C, Lauterborn J, Isackson P, et al. Seizures, neuropeptide regulation, and mRNA expression in the hippocampus. Prog Brain Res 1990;83: 37190.
  • 20
    Schwarzer C, Sperk G, Samanin R, et al. Neuropeptides-immunoreactivity and their mRNA expression in kindling: functional implications for limbic epileptogenesis. Brain Res Rev 1996;22: 2750.
  • 21
    Wasterlain CG, Mazarati AM, Naylor D, et al. Short-term plasticity of hippocampal neuropeptides and neuronal circuitry in experimental status epilepticus. Epilepsia 2002;43(suppl 5):209.
  • 22
    White JD, Gall CM. Differential regulation of neuropeptide and proto-oncogene mRNA content in the hippocampus following recurrent seizures. Brain Res 1987;427: 219.
  • 23
    Gall C. Seizures induce dramatic and distinctly different changes in enkephalin, dynorphin, and CCK immunoreactivities in mouse hippocampal mossy fibers. J Neurosci 1988;8: 185262.
  • 24
    Sperk G, Marksteiner J, Gruber B, et al. Functional changes in neuropeptide Y- and somatostatin-containing neurons induced by limbic seizures in the rat. Neuroscience 1992;50: 83146.
  • 25
    Vezzani A, Sperk G, Colmers WF. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci 1999;22: 2530.
  • 26
    Adams JC. Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. J Histochem Cytochem 1992;40: 145763.
  • 27
    Theodorsson E, Rugarn O. Radioimmunoassay for rat galanin: immunochemical and chromatographic characterization of immunoreactivity in tissue extracts. Scand J Clin Lab Invest 2000;60: 4118.
  • 28
    Christensson-Nylander I, Herrera-Marschitz M, Staines W, et al. Striato-nigral dynorphin and substance P pathways in the rat. I. Biochemical and immunohistochemical studies. Exp Brain Res 1986;64: 16992.
  • 29
    Schultzberg M, Lundberg JM, Hökfelt T, et al. Enkephalin-like immunoreactivity in gland cells and nerve terminals of the adrenal medulla. Neuroscience 1978;3: 116986.
  • 30
    Weber E, Evans CJ, Barchas JD. Predominance of the amino-terminal octapeptide fragment of dynorphin in rat brain regions. Nature 1982;299: 779.
  • 31
    Frey P. Cholecystokinin octapeptide (CCK 26-33), nonsulfated octapeptide and tetrapeptide (CCK 30-33) in the rat brain: analysis by high pressure liquid chromatography (HPLC) and radioimmunoassay (RIA). Neurochem Int 1983;5: 8115.
  • 32
    Wenzel HJ, Cole TB, Born DE, et al. Ultrastructural localization of zinc transporter-3 (ZnT-3) to synaptic vesicle membranes within mossy fiber boutons in the hippocampus of mouse and monkey. Proc Natl Acad Sci U S A 1997;94: 1267681.
  • 33
    Vrontakis ME, Peden LM, Duckworth ML, et al. Isolation and characterization of a complementary DNA (galanin) clone from estrogen-induced pituitary tumor messenger RNA. J Biol Chem 1987;262: 167558.
  • 34
    Howells RD, Kilpatrick DL, Bhatt R, et al. Molecular cloning and sequence determination of rat preproenkephalin cDNA: sensitive probe for studying transcriptional changes in rat tissues. Proc Natl Acad Sci U S A 1984;81: 76515.
  • 35
    Larhammar D, Ericsson A, Persson H. Structure and expression of the rat neuropeptide Y gene. Proc Natl Acad Sci U S A 1987;84: 206872.
  • 36
    Deschenes RJ, Lorenz LJ, Haun RS, et al. Cloning and sequence analysis of a cDNA encoding rat preprocholecystokinin. Proc Natl Acad Sci U S A 1984;81: 72630.
  • 37
    Krause JE, Chirgwin JM, Carter MS, et al. Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A. Proc Natl Acad Sci U S A 1987;84: 8815.
  • 38
    Civelli O, Douglass J, Goldstein A, et al. Sequence and expression of the rat prodynorphin gene. Proc Natl Acad Sci U S A 1985;82: 42915.
  • 39
    Schalling M, Seroogy K, Hökfelt T, et al. Neuropeptide tyrosine in the rat adrenal gland: immunohistochemical and in situ hybridization studies. Neuroscience 1988;24: 33749.
  • 40
    Dagerlind Å, Friberg K, Bean AJ, et al. Sensitive mRNA detection using unfixed tissue: combined radioactive and non-radioactive in situ hybridization histochemistry. Histochemistry 1992;98: 3949.
  • 41
    O'Donnell D, Ahmad S, Wahlestedt C, et al. Expression of the novel galanin receptor subtype GALR2 in the adult rat CNS: distinct distribution from GALR1. J Comp Neurol 1999;409: 46981.
  • 42
    Olney JW, Collins RC, Sloviter RS. Excitotoxic mechanisms of epileptic brain damage. Adv Neurol 1986;44: 85777.
  • 43
    Represa A, Ben-Ari Y. Kindling is associated with the formation of novel mossy fibre synapses in the CA3 region. Exp Brain Res 1992;92: 6978.
  • 44
    Skofitsch G, Sills MA, Jacobowitz DM. Autoradiographic distribution of 125I-galanin binding sites in the rat central nervous system. Peptides 1986;7: 102942.
  • 45
    Melander T, Köhler C, Nilsson S, et al. Autoradiographic quantitation and anatomical mapping of 125I-galanin binding sites in the rat central nervous system. J Chem Neuroanat 1988;1: 21333.
  • 46
    Holets VR, Hökfelt T, Rökaeus Å, et al. Locus coeruleus neurons in the rat containing neuropeptide Y, tyrosine hydroxylase or galanin and their efferent projections to the spinal cord, cerebral cortex and hypothalamus. Neuroscience 1988;24: 893906.
  • 47
    Fredens K, Stengaard-Pedersen K, Wallace MN. Localization of cholecystokinin in the dentate commissural-associational system of the mouse and rat. Brain Res 1987;401: 6878.
  • 48
    Liu HX, Brumovsky P, Schmidt R, et al. Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: selective actions via GalR1 and GalR2 receptors. Proc Natl Acad Sci U S A 2001;98: 99604.
  • 49
    Tonder N, Kragh J, Finsen BR, et al. Kindling induces transient changes in neuronal expression of somatostatin, neuropeptide Y, and calbindin in adult rat hippocampus and fascia dentata. Epilepsia 1994;35: 1299308.
  • 50
    Kopp J, Nanobashvili A, Kokaia Z, et al. Differential regulation of mRNAs for neuropeptide Y and its receptor subtypes in widespread areas of the rat limbic system during kindling epileptogenesis. Mol Brain Res 1999;72: 1729.
  • 51
    Vezzani A, Schwarzer C, Lothman EW, et al. Functional changes in somatostatin and neuropeptide Y containing neurons in the rat hippocampus in chronic models of limbic seizures. Epilepsy Res 1996;26: 26779.
  • 52
    Grüber B, Greber S, Rupp E, et al. Differential NPY mRNA expression in granule cells and interneurons of the rat dentate gyrus after kainic acid injection. Hippocampus 1994;4: 47482.
  • 53
    Baraban SC, Hollopeter G, Erickson JC, et al. Knock-out mice reveal a critical antiepileptic role for neuropeptide Y. J Neurosci 1997;17: 892736.
  • 54
    Colmers WF, Klapstein GJ, Fournier A, et al. Presynaptic inhibition by neuropeptide Y in rat hippocampal slice in vitro is mediated by a Y2 receptor. Br J Pharmacol 1991;102: 414.
  • 55
    Greber S, Schwarzer C, Sperk G. Neuropeptide Y inhibits potassium-stimulated glutamate release through Y2 receptors in rat hippocampal slices in vitro. Br J Pharmacol 1994;113: 73740.
  • 56
    Woldbye DP, Larsen PJ, Mikkelsen JD, et al. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nat Med 1997;3: 7614.
  • 57
    Scharfman HE, Sollas AL, Goodman JH. Spontaneous recurrent seizures after pilocarpine-induced status epilepticus activate calbindin-immunoreactive hilar cells of the rat dentate gyrus. Neuroscience 2002;111: 7181.
  • 58
    Gariboldi M, Conti M, Cavaleri D, et al. Anticonvulsant properties of BIBP3226, a non-peptide selective antagonist at neuropeptide Y Y1 receptors. Eur J Neurosci 1998;10: 7579.
  • 59
    Vezzani A, Civenni G, Rizzi M, et al. Enhanced neuropeptide Y release in the hippocampus is associated with chronic seizure susceptibility in kainic acid treated rats. Brain Res 1994;660: 13843.
  • 60
    Douglass J, Grimes L, Shook J, et al. Systemic administration of kainic acid differentially regulates the levels of prodynorphin and proenkephalin mRNA and peptides in the rat hippocampus. Mol Brain Res 1991;9: 7986.
  • 61
    Harrison MB, Shumate MD, Lothman EW. Opioid peptide expression in models of chronic temporal lobe epilepsy. Neuroscience 1995;65: 78595.
  • 62
    Hong JS, Wood PL, Gillin JC, et al. Changes of hippocampal met-enkephalin content after recurrent motor seizures. Nature 1980;285: 2312.
  • 63
    Simpson JN, Zhang WQ, Bing G, et al. Kainic acid-induced sprouting of dynorphin- and enkephalin-containing mossy fibers in the dentate gyrus of the rat hippocampus. Brain Res 1997;747: 31823.
  • 64
    Wagner JJ, Terman GW, Chavkin C. Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus. Nature 1993;363: 4514.
  • 65
    Weisskopf MG, Zalutsky RA, Nicoll RA. The opioid peptide dynorphin mediates heterosynaptic depression of hippocampal mossy fibre synapses and modulates long-term potentiation. Nature 1993;362: 4237.
  • 66
    Simmons ML, Chavkin C. Endogenous opioid regulation of hippocampal function. Int Rev Neurobiol 1996;39: 14596.
  • 67
    Madison DV, Nicoll RA. Enkephalin hyperpolarizes interneurones in the rat hippocampus. J Physiol 1988;398: 12330.
  • 68
    Borhegyi Z, Leranth C. Substance P innervation of the rat hippocampal formation. J Comp Neurol 1997;384: 4158.
  • 69
    Liu H, Mazarati AM, Katsumori H, et al. Substance P is expressed in hippocampal principal neurons during status epilepticus and plays a critical role in the maintenance of status epilepticus. Proc Natl Acad Sci U S A 1999;96: 528691.
  • 70
    Liu H, Cao Y, Basbaum AI, et al. Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene. Proc Natl Acad Sci U S A 1999;96: 12096101.
  • 71
    Gall CM, Pico RM, Lauterborn JC. Focal hippocampal lesions induce seizures and long-lasting changes in mossy fiber enkephalin and CCK immunoreactivity. Peptides 1988;9(suppl 1):7984.
  • 72
    Petersson S, Lavebratt C, Schalling M, et al. Expression of cholecystokinin, enkephalin, galanin and neuropeptide Y is markedly changed in the brain of the megencephaly mouse. Neuroscience 2000;100: 297317.
  • 73
    Aitken PG, Jaffe DB, Nadler JV. Cholecystokinin blocks some effects of kainic acid in CA3 region of hippocampal slices. Peptides 1991;12: 1279.
  • 74
    Kadar T, Pesti A, Penke B, et al. Structure-activity and dose-effect relationships of the antagonism of picrotoxin-induced seizures by cholecystokinin, fragments and analogues of cholecystokinin in mice. Neuropharmacology 1983;22: 12239.
  • 75
    Zetler G. Anticonvulsant effects of caerulein, cholecystokinin octapeptide (CCK-8) and diazepam against seizures produced in mice by harman, thiosemicarbazide and isoniazid. Neurosci Lett 1981;24: 17580.
  • 76
    Sinton CM. Cholecystokinin and cholecystokinin antagonists enhance postsynaptic excitability in the dentate gyrus. Peptides 1988;9: 104953.
  • 77
    Dodd J, Kelly JS. The actions of cholecystokinin and related peptides on pyramidal neurones of the mammalian hippocampus. Brain Res 1981;205: 33750.